| Literature DB >> 34191805 |
Btissam Arhoune1, Samira El Fakir2, Sara Himri1, Kaoutar Moutaouakkil1, Salma El Hassouni1, Moussa Benboubker1, Fouzia Hmami3, Bouchra Oumokhtar1.
Abstract
This study was conducted in order to know the colonization rate of MDR enterobacteria in neonates during their hospitalization in neonatal intensive care unit (NICU). Furthermore, we investigated risk factors for potential colonization and molecular epidemiology of isolated resistant bacteria. This prospective study was carried out in the neonatology and intensive care unit department of the University Hospital of Fez (Morocco) from February 2013 to July 2015. All consecutive admitted newborns were screened for intestinal and nasal carriage of MDR enterobacteria at admission of the babies and during the hospitalization. During the study period, a total of 641 Enterobacteriaceae were isolated and Klebsiella pneumoniae was the predominated bacteria. Bacterial identification and antibiograms were performed according to the international standards. On admission, 455 newborns were screened. A median age of these newborns was 1 day with an extended 147 days and their average weight was 2612 ± 1023 grams. 22.4% of neonates were found colonized by an ESBL producing Enterobacteriaceae (ESBL-E), 8.7% by a carbapenemases producing Enterobacteriaceae (CPE). During hospitalization, 207 of newborns were included in the acquisition study. 59.4% of newborns acquired an ESBL-E during their stay, 12.5% has acquired CPE. The blaCTXM-15 gene was the most frequently detected (81.2%) among ESBL-E. While, all CPE has expressed the blaOXA-48 gene exclusively. Two risk factors have been significantly associated with MDR enterobacteria colonization at admission which are newborns admission from maternity of the university hospital (95% CI, 1.859-5.129, P = 0.000) and neurological distress (95% CI, 1.038 to 4.694, P = 0.040). During hospitalization, the none risk factor was significantly associated with the carriage of MDR-E. The high rate of colonization, the MDR enterobacteria and the resistance genes found represent good indicator of cross-transmission in the NICU. An active strategy to control the spread of MDR enterobacteria should be applied.Entities:
Year: 2021 PMID: 34191805 PMCID: PMC8244853 DOI: 10.1371/journal.pone.0251810
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Flowchart of the patients.
Prevalence of ESBL and CARBA carriage among newborns hospitalised in NICU.
| Carriers at admission | Colonised during NICU stay | |
|---|---|---|
| ESBL | 22.4 (102/455) | 59.4 (123/207) |
| ESBL | 77.4 (79/102) | 94.3 (116/123) |
| ESBL | 32.3 (33/102) | 26 (32/123) |
| ESBL | 8.8 (9/102) | 8.1 (10/123) |
| CARBA | 8.7 (40) | 12.5 (26/207) |
| CARBA | 42.5 (17/40) | 46.1 (12/26) |
| CARBA | 45 (18/40) | 61.5 (16/26) |
| CARBA | 12.5 (5/40) | 7.6 (2/26) |
*Carriage of at least one MDR Enterobacteriaceae isolate.
Association between patient’s characteristics and prevalence of multidrug-resistant Enterobacteriaceae carriage on the day of admission and during hospitalization at NICU.
| At admission | During NICU stay | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Category | Patients numbers (%) | MDR-EB - | MDR-EB + | p-value | Patients numbers (%) | MDR-EB - | MDR-EB + | p-value | |
| n = 455 | [N (%)] | [N (%)] | n = 207 | [N (%)] | [N (%)] | ||||
| Male | 267 (58.7) | 180 (59) | 87 (58) | 0.457 | 124 (59.9) | 36 (65.5) | 88 (57.9) | 0.207 | |
| Female | 188 (41.3) | 125 (41) | 63 (42) | 83 (40.1) | 19 (34.5) | 64 (42.1) | |||
| 0–2 | Mean±SD | 222 (72.8) | 86 (57.3) | Mean±SD | 39 (70.9) | 112 (73.7) | 0.408 | ||
| > 2 | 6.5±15.8 | 83 (27.2) | 64 (42.7) | 5.1±12.2 | 16 (29.1) | 40 (26.3) | |||
| Yes | 224 (49.2) | 156 (51.1) | 68 (45.3) | 0.140 | 113 (54.6) | 29 (52.7) | 84 (55.3) | 0.433 | |
| No | 231 (50.8) | 149 (48.9) | 82 (54.7) | 94 (45.4) | 26 (47.3) | 68 (44.7) | |||
| < 2500 | Mean±SD | 158 (51.8) | 68 (45.3) | 0.115 | Mean±SD | 31 (56.4) | 81 (53.3) | 0.408 | |
| ≥ 2500 | 2612±1026g | 147 (48.2) | 82 (54.7) | 2466±975 | 24 (43.6) | 71 (46.7) | |||
| Respiratory distress | 259 (56.9) | 182 (59.7) | 77 (51.3) | 123 (59.4) | 32 (58.2) | 91 (59.9) | 0.475 | ||
| Icterus | 38 (8.4) | 21 (6.9) | 17 (11.3) | 0.078 | 14 (6.8) | 2 (3.6) | 12 (7.9) | 0.229 | |
| Surgical pathology | 31 (6.8) | 17 (5.6) | 14 (9.3) | 0.099 | 11 (5.3) | 4 (7.3) | 7 (4.6) | 0.328 | |
| Neonatal suffering | 34 (7.5) | 24 (7.9) | 10 (6.7) | 0.401 | 16 (7.7) | 4 (7.3) | 12 (7.9) | 0.573 | |
| Neonatal infections | 35 (7.7) | 20 (6.6) | 15 (10) | 0.134 | 16 (7.7) | 3 (5.5) | 13 (8.6) | 0.342 | |
| Neurological distress | 44 (9.7) | 34 (11.1) | 10 (6.7) | 0.086 | 22 (10.6) | 3 (5.5) | 19 (12.5) | 0.112 | |
| Congenital malformations | 11 (2.4) | 9 (3) | 2 (1.3) | 0.239 | 6 (2.9) | 2 (3.6) | 4 (2.6) | 0.505 | |
| Others | 49 (10.8) | 29 (9.5) | 20 (13.3) | 0.141 | 18 (8.7) | 7 (12.7) | 11 (7.2) | 0.168 | |
| Maternity of UH Fez | 265 (58.2) | 190 (41.8) | 75 (50) | 125 (60.4) | 33 (60) | 92 (60.5) | 0.703 | ||
| Other hospital | 164 (36) | 97 (31.8) | 67 (44.7) | 66 (31.9) | 19 (34.5) | 47 (30.9) | |||
| Home | 26 (5.7) | 18 (5.9) | 8 (5.3) | 16 (7.7) | 3 (5.5) | 13 (8.6) | |||
| Maternity of UH Fez | 235 (51.6) | 178 (58.4) | 57 (38) | 117 (56.5) | 31 (56.4) | 86 (56.6) | 0.870 | ||
| Other hospital | 124 (27.3) | 77 (25.2) | 47 (31.3) | 56 (27.1) | 16 (29.1) | 40 (26.3) | |||
| Home | 96 (21.1) | 50 (16.4) | 46 (30.7) | 34 (16.4) | 8 (14.5) | 26 (17.1) | |||
| vaginal | 310 (68.1) | 205 (67.2) | 105 (70) | 0.312 | 142 (68.6) | 34 (61.8) | 108 (71.1) | 0.137 | |
| Caesarean section | 145 (31.9) | 100 (32.8) | 45 (30) | 65 (31.4) | 21 (38.2) | 44 (28.9) | |||
| peripheral | -- | -- | -- | -- | 203 (98.1) | 55 (100) | 148 (97.4) | 0.288 | |
| central | -- | -- | -- | 4 (1.9) | 0 (0) | 4 (2.6) | |||
| Breastfed newborn | 179 (39.3) | 111 (36.4) | 68 (45.3) | 69 (33.3) | 17 (30.9) | 52 (34.2) | 0.394 | ||
| Diet newborn | 276 (60.7) | 194 (63.6) | 82 (54.7) | 138 (66.7) | 38 (69.1) | 100 (65.8) | |||
| Ceftriaxone+gentamicin | -- | -- | -- | -- | 116 (56) | 35 (63.6) | 81 (53.3) | 0.121 | |
| Aximicin+gentamicin | -- | -- | -- | 74 (35.7) | 18 (32.7) | 56 (36.8) | 0.354 | ||
*Carriage of at least one MDR Enterobacteriaceae isolate
**Neonates may have more than one reason for hospitalization.
Multivariable analysis for MDR-Enterobacteriaceae carriage at NICU admission and acquisition during hospitalization.
| Variable | Multivariable analysis for MDR | |
|---|---|---|
| OR (95%CI) | P value | |
| 2.207 (1.038–4.694) | 0.040 | |
| 3.088 (1.859–5.129) | 0.000 | |
| 2.010 (1.251–3.230) | 0.004 | |
Resistance profiles of the different Enterobacteriaceae isolated on admission and during hospitalization.
| No. (%) of resistant isolates at admission | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| AMX | AMC | FOX | CTX/CAZ | GN | AK | NA | NOR/CIP | SXT | ETP | |
| 88 | 65 | 36 | 56 | 51 | 2 | 53 | 46 | 38 | 18 | |
| 124 | 80 | 3 | 79 | 72 | 0 | 39 | 39 | 49 | 17 | |
| 9 | 7 | 0 | 7 | 5 | 6 | 4 | ||||
| 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | |
| 3 | 2 | 1 | 2 | 2 | 1 | 0 | ||||
| 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| 236 (75.3) | 169 (53.9) | 62 (19.8) | 149 (47.6) | 133 (42.4) | 3 (0.9) | 102 (32.5) | 93 (29.7) | 95 (30.3) | 40 (12.7) | |
| 195 | 184 | 10 | 184 | 169 | 0 | 95 | 90 | 99 | 18 | |
| 100 | 96 | 63 | 93 | 89 | 9 | 79 | 77 | 28 | 26 | |
| 6 | 3 | 1 | 3 | 3 | 3 | 2 | ||||
| 5 | 1 | 5 | 5 | 0 | 2 | 2 | 3 | 2 | ||
| 4 | 3 | 0 | 1 | 1 | 0 | 1 | ||||
| 4 | 3 | 0 | 2 | 2 | 0 | 2 | 0 | 0 | 0 | |
| 1 | 1 | 0 | 0 | 0 | 0 | 0 | ||||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| 319 (97.2) | 302 (92) | 88 (26.8) | 295 (89.9) | 272 (82.9) | 10 (3) | 182 (55.4) | 173 (52.7) | 133 (40.5) | 49 (14.9) | |
*Natural resistance
AMP: ampicillin; AMC: amoxicillin / clavulanic acid; FOX: cefoxitin; CTX: cefotaxim; CAZ: ceftazidim; GN: gentamicin; AK: amikacin; NA: nalidixic acid; NOR: norfloxacin; CIP: ciprofloxacin, SXT: cotrimoxazol; ETP: ertapenem.